BRIEF-Galapagos And Adaptimmune Sign Clinical Collaboration Agreement With An Option To Exclusively License Adaptimmune’s Uza-Cel In Head & Neck Cancer And Potential Future Solid Tumor Indications

Adaptimmune Therapeutics PLC Sponsored ADR -0.79%
Galapagos NV Sponsored ADR +2.39%
Dow Jones Industrial Average +0.59%
S&P 500 index -1.39%
NASDAQ -2.77%

Adaptimmune Therapeutics PLC Sponsored ADR

ADAP

1.26

-0.79%

Galapagos NV Sponsored ADR

GLPG

27.00

+2.39%

Dow Jones Industrial Average

DJI

41198.08

+0.59%

S&P 500 index

SPX

5588.27

-1.39%

NASDAQ

IXIC

17996.92

-2.77%

- Adaptimmune Therapeutics PLC ADAP.O:

  • REG-GALAPAGOS AND ADAPTIMMUNE SIGN CLINICAL COLLABORATION AGREEMENT WITH AN OPTION TO EXCLUSIVELY LICENSE ADAPTIMMUNE’S TCR T-CELL THERAPY CANDIDATE, UZA-CEL, IN HEAD & NECK CANCER AND POTENTIAL FUTURE SOLID TUMOR INDICATIONS

  • GALAPAGOS NV: ADAPTIMMUNE TO RECEIVE INITIAL PAYMENTS OF $100 MILLION

  • GALAPAGOS NV: ADAPTIMMUNE TO RECEIVE ADDITIONAL DEVELOPMENT AND SALES MILESTONE PAYMENTS OF UP TO A MAXIMUM OF $465 MILLION

  • GALAPAGOS NV: GALAPAGOS HAS BEEN GRANTED AN OPTION TO EXCLUSIVELY LICENSE UZA-CEL FOR GLOBAL DEVELOPMENT AND COMMERCIALIZATION IN HEAD & NECK CANCER

  • GALAPAGOS NV-GRANTED OPTION TO EXCLUSIVELY LICENSE UZA-CEL FOR GLOBAL DEVELOPMENT,COMMERCIALIZATION IN POTENTIAL FUTURE SOLID TUMOR CANCER INDICATIONS

Source text for Eikon: ID:nGNE82GRm0

Further company coverage: ADAP.O


((Reutersbriefs@thomsonreuters.com;))

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via